EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development and External Validation of a Predictive Model for Postoperative Recurrence of Crohn’s Disease in the Biologic Era

Matthieu Allez, Michiel T J Bak, Sofia Brand, Laura Diebakate-Scordamaglia, Elisabeth Capelle, Philippe Seksik, Stéphane Nancey, Jean-Marc Gornet, Anthony Buisson, Franck Carbonnel, Laurent Peyrin-Biroulet, Edouard Louis und 18 weitere

Clinical Gastroenterology and Hepatology · 2026-03

DOI: 10.1016/j.cgh.2026.03.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-03. Verfasst von Matthieu Allez und 29 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute, McGill University Health Centre (MUHC), Montreal, Quebec, Canada; Department of Gastroenterology, Hôpital Saint-Louis, APHP, Pari…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, MSD, The Leona M and Harry B Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Ileocolonic resection remains common in Crohn's disease (CD) despite increasing biologic use. The aim of this study was to identify risk factors for postoperative recurrence and to assess prophylactic biologic therapy effectiveness in relation to risk factors. METHODS: This prospective multicentre study included adults with CD undergoing ileocolonic resection (ICR). The primary endpoint was endoscopic recurrence (modified Rutgeerts score ≥i2b) within the year following surgery. Factors associated with endoscopic recurrence were identified using a logistic regression model. A composite time-to-event endpoint was defined for long-term follow-up based on clinical, endoscopic, and/or imaging data. An external validation of our predictive model was performed in 2 independent international cohorts. RESULTS: Among 632 patients (median disease duration, 7.8 years), 78% had prior biologic exposure; 44% received postoperative biologic prophylaxis. Endoscopic recurrence occurred in 237 patients (37.5%). In multivariable model, risk factors included: male sex (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.38-2.83), active smoking (OR, 2.37; 95% CI, 1.56-3.62), previous ICR (OR, 1.78; 95% CI, 1.13-2.82), previous exposure to 1 (OR, 2.15; 95% CI, 1.37-3.42) or more than 1 biologic (OR, 2.41; 95% CI, 1.39-4.22). Biologic prophylaxis significantly reduced recurrence risk (OR, 0.31; 95% CI, 0.20-0.45), independently of these risk factors. A predictive nomogram based on multivariable analysis achieved an area under the receiver operating characteristic curve of 0.72, with similar performance in external cohorts. Clinically significant recurrence, observed in 22.9%, 36.5%, and 53.2% at 3, 5, and 10 years, was associated with severity of early endoscopic recurrence. CONCLUSIONS: Postoperative recurrence risk can be estimated using a model based on clinical factors. Biologic prophylaxis is highly effective in preventing early endoscopic recurrence, regardless of risk profile. CLINICALTRIALS: gov, Number: NCT03458195.

Schlagwörter

Stichwörter der Autor:innen

Biologic TherapiesCrohn’s DiseaseEndoscopic RecurrenceIleocolonic SurgeryProphylaxis

Autor:innen und Institutionen

  • Research Institute, McGill University Health Centre (MUHC), Montreal, Quebec, Canada; Department of Gastroenterology, Hôpital Saint-Louis, APHP, Paris, France; INSERM U1342, Institut de Recherche Saint-Louis, Université…
  • Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Biostatistics, SBIM, Saint-Louis Hospital, Paris, France.
  • Research Institute, McGill University Health Centre (MUHC), Montreal, Quebec, Canada.
  • Department of Gastroenterology, Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Paris, France; Gut, Liver & Microbiome Research (GLIMMER) FHU, Paris, France.
  • Department of Gastroenterology, Hôpital Lyon-Sud, Hospices Civils de Lyon, University Lyon1, INSERM U1111, CIRI, Lyon, France.

Förderung

  • NIDDK NIH HHS
  • MSD
  • The Leona M and Harry B Helmsley Charitable Trust
  • Association François Aupetit
  • Takeda Pharmaceutical Company

Zitieren

APA

Allez, M., Bak, M. T. J., Brand, S., Diebakate-Scordamaglia, L., Capelle, E., Seksik, P., Nancey, S., Gornet, J. M., Buisson, A., Carbonnel, F., Peyrin-Biroulet, L., Louis, E., Hébuterne, X., Serrero, M., Bourreille, A., Treton, X., Wils, P., Fumery, M., Blanc, P., …, & Hammoudi, N. (2026). Development and External Validation of a Predictive Model for Postoperative Recurrence of Crohn’s Disease in the Biologic Era. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.03.015

Vancouver

Allez M, Bak MTJ, Brand S, Diebakate-Scordamaglia L, Capelle E, Seksik P, et al. Development and External Validation of a Predictive Model for Postoperative Recurrence of Crohn’s Disease in the Biologic Era. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.03.015

BibTeX
@article{Allez2026,
  author = {Allez, Matthieu and Bak, Michiel T J and Brand, Sofia and Diebakate-Scordamaglia, Laura and Capelle, Elisabeth and Seksik, Philippe and Nancey, Stéphane and Gornet, Jean-Marc and Buisson, Anthony and Carbonnel, Franck and Peyrin-Biroulet, Laurent and Louis, Edouard and Hébuterne, Xavier and Serrero, Mélanie and Bourreille, Arnaud and Treton, Xavier and Wils, Pauline and Fumery, Mathurin and Blanc, Pierre and Uzzan, Mathieu and Sokol, Harry and Barnich, Nicolas and Kirchgesner, Julien and Colombel, Jean-Frédéric and Maggiori, Léon and Bezault, Madeleine and Silverberg, Mark S and De Vries, Annemarie C and Lambert, Jérome and Hammoudi, Nassim},
  title = {Development and External Validation of a Predictive Model for Postoperative Recurrence of Crohn’s Disease in the Biologic Era},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.03.015}
}
Kostenlos starten →